AstraZeneca May Market Unbranded Tamoxifen If Barr Contract Not Resumed
Executive Summary
Nolvadex maker AstraZeneca may market its own tamoxifen generic if it cannot reach an agreement with Barr to reinstate the companies' supply and distribution agreement
You may also be interested in...
AstraZeneca Self-Markets Nolvadex Generic; Zoladex Settlement Near
AstraZeneca is marketing its own generic version of Nolvadex (tamoxifen) to protect the company from claims that it is exploiting cancer patients in the final months of exclusivity for the drug
AstraZeneca Self-Markets Nolvadex Generic; Zoladex Settlement Near
AstraZeneca is marketing its own generic version of Nolvadex (tamoxifen) to protect the company from claims that it is exploiting cancer patients in the final months of exclusivity for the drug
Barr Tamoxifen Off Market Until February; Company May Seek Damages
Barr is considering suing AstraZeneca for damages after a federal court sided with FDA in denying its request to begin marketing a generic version of Nolvadex